BCMA Test Your Knowledge

Test Your Knowledge

Quiz: How Do Patients With MM Who Received Anti-BCMA Therapy Respond to COVID-19 Vaccinations?

12/01/2021

True or false: Patients with MM who received anti-BCMA antibody-based therapy were associated with having a lack of T-cell responses following SARS-CoV-2 vaccination.

True or false: Patients with MM...

12/01/2021

Oncology

Quiz

Quiz: Which of the Following Inhibitors Target BCMA in MM?

11/10/2021

Which of the following inhibitors showed an increase in BCMA surface density and a decrease in soluble BCMA levels?

Which of the following...

11/10/2021

Oncology

Test Your Knowledge

Quiz: Is Extramedullary Disease Associated with Poor Prognoses in R/R MM?

11/02/2021

True or false: In R/R MM, extramedullary disease is linked to significantly poor prognoses.

True or false: In R/R MM,...

11/02/2021

Oncology

Quiz

Quiz: Can Anti-BCMA CAR-T Cell Therapy Cause Humoral Immune Deficiencies in R/R MM?

10/14/2021

True or false: A profound and lasting humoral immune deficiency was found after anti-BCMA CAR-T cell therapy in patients with R/R MM.

True or false: A profound and...

10/14/2021

Oncology

Test Your Knowledge

Quiz: Which Cell Type is Known for BCMA Expression?

09/20/2021

Which of the following cell type is known for BCMA expression?

Which of the following cell type...

09/20/2021

Oncology

Test Your Knowledge

Quiz: Responses to BCMA-Directed CAR-T Therapy for R/R MM

09/07/2021

True or false: Results from the CARTITUDE-1 trial showed that BCMA-directed CAR-T therapy yielded early, deep, and durable responses in patients with R/R MM.

True or false: Results from the...

09/07/2021

Oncology

Test Your Knowledge

Quiz: Does Teclistamab Therapy Display Promise in BCMA-Positive MM?

11/19/2020

True or False: Data suggest that teclistamab is a promising therapy for patients with BCMA-positive MM.

True or False: Data suggest that...

11/19/2020

Oncology

Test Your Knowledge

Quiz: The Basics of BCMA Expression in Multiple Myeloma

10/08/2020

True or False: BCMA is expressed in nearly all MM tumor cells and serves as a potential biomarker for identifying malignant plasma cells in this patient population.

True or False: BCMA is expressed...

10/08/2020

Oncology

Test Your Knowledge

Quiz: Promising Role of BCMA-Directed CAR-T Therapy for R/R MM

09/25/2020

True or False: According to data from the CARTITUDE-1 trial, the BCMA-directed CAR-T therapy JNJ‑4528 was very effective and yielded 100% overall response rate in patients with relapsed or refractory MM.

True or False: According to data...

09/25/2020

Oncology

Test Your Knowledge

Quiz: Can BCMA-Targeting CAR T-Cells Improve Patient Outcomes in MM?

08/26/2020

True or False: Multiple studies have demonstrated positive results with BCMA-targeting CAR T-cells for the treatment of relapsed and refractory MM.

True or False: Multiple studies...

08/26/2020

Oncology

Recent News

News

Datopotamab Deruxtecan Approved for HR-Positive, HER2-Negative Breast Cancer

01/17/2025

Allison Casey ;

The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...

The US Food and Drug...

01/17/2025

Oncology

FDA Alerts

Sotorasib Plus Panitumumab Approved for Patients With KRAS G12C-Mutated Colorectal Cancer

01/17/2025

Stephanie Holland ;

Based on results from the phase 3 CodeBreaK 300 trial, the FDA has approved sotorasib plus panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer.

Based on results from the phase...

01/17/2025

Oncology

FDA Approval

FDA Approves Acalabrutinib With Bendamustine and Rituximab for Patients With Previously Untreated MCL

01/17/2025

Gina Tomaine ;

The FDA granted approval to acalabrutinib with bendamustine and rituximab for patients with previously untreated mantle cell lymphoma ineligible for autologous hematopoietic stem cell transplantation.

The FDA granted approval to...

01/17/2025

Oncology

News

Presence of Circulating Lymphoma Cells May Be Associated With Worse Survival Outcomes for Newly Diagnosed Patients With DLBCL

01/16/2025

Emily Estrada ;

Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.

Inferior survival outcomes are...

01/16/2025

Oncology

News

Ciltacabtagene Autoleucel Demonstrates Efficacy for Patients With R/R Multiple Myeloma in Real-World Population

01/15/2025

Emily Estrada ;

Treatment with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma demonstrated feasibility and efficacy in a real-world setting, according to recent study results.

Treatment with ciltacabtagene...

01/15/2025

Oncology

News

Addition of Nab-Paclitaxel to Standard Gemcitabine and Cisplatin Did Not Significantly Improve Survival for Patients With Newly Diagnosed Biliary Tract Cancer

01/14/2025

Stephanie Holland ;

According to results from the phase 3 SWOG-S1815 study, the addition of nab-paclitaxel to gemcitabine plus cisplatin did not significantly improve survival outcomes for patients with newly diagnosed advanced biliary tract cancer.

According to results from the...

01/14/2025

Oncology

News

First-line Eribulin Plus Trastuzumab and Pertuzumab for Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer

01/14/2025

Stephanie Holland ;

According to results from the phase 3 EMERALD trial, eribulin plus trastuzumab and pertuzumab demonstrated promising efficacy as a first-line option for patients with HER2-positive locally advanced or metastatic breast cancer.

According to results from the...

01/14/2025

Oncology

News

Avelumab Plus Axitinib Demonstrates Long-Term Efficacy, Safety for Patients With Advanced Renal Cell Carcinoma

01/08/2025

Stephanie Holland ;

Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.

Final results from the phase 3...

01/08/2025

Oncology

News

Neratinib Demonstrates Promising Efficacy for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

01/08/2025

Stephanie Holland ;

According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.

According to results from the...

01/08/2025

Oncology

News

Nivolumab Plus Ipilimumab Prolonged Progression-Free Survival for Patients with MSI-H/dMMR Metastatic Colorectal Cancer

01/06/2025

Stephanie Holland ;

Interim analysis results from the phase 3 CheckMate 8HW trial demonstrated that nivolumab plus ipilimumab prolonged progression-free survival compared to chemotherapy alone among patients with microsatellite instability-high or mismatch...

Interim analysis results from...

01/06/2025

Oncology